Premium
CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study
Author(s) -
Ewers Michael,
Mattsson Niklas,
Minthon Lennart,
Molinuevo José L.,
Antonell Anna,
Popp Julius,
Jessen Frank,
Herukka SannaKaisa,
Soininen Hilka,
Maetzler Walter,
Leyhe Thomas,
Bürger Katharina,
Taniguchi Miyako,
Urakami Katsuya,
Lista Simone,
Dubois Bruno,
Blennow Kaj,
Hampel Harald
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.12.006
Subject(s) - dementia , vascular dementia , dementia with lewy bodies , lewy body , medicine , cerebrospinal fluid , differential diagnosis , memory clinic , alzheimer's disease , depression (economics) , disease , frontotemporal dementia , medical diagnosis , oncology , pathology , psychiatry , economics , macroeconomics
The aim of this study was to test the diagnostic value of cerebrospinal fluid (CSF) beta‐amyloid (Aβ 1–42 ), phosphorylated tau, and total tau (tau) to discriminate Alzheimer's disease (AD) dementia from other forms of dementia. Methods A total of 675 CSF samples collected at eight memory clinics were obtained from healthy controls, AD dementia, subjective memory impairment, mild cognitive impairment, vascular dementia, Lewy body dementia (LBD), fronto‐temporal dementia (FTD), depression, or other neurological diseases. Results CSF Aβ 1–42 showed the best diagnostic accuracy among the CSF biomarkers. At a sensitivity of 85%, the specificity to differentiate AD dementia against other diagnoses ranged from 42% (for LBD, 95% confidence interval or CI = 32–62) to 77% (for FTD, 95% CI = 62–90). Discussion CSF Aβ 1–42 discriminates AD dementia from FTD, but shows significant overlap with other non‐AD forms of dementia, possibly reflecting the underlying mixed pathologies.